• Alder shares slump despite migraine success pharmaphorum
    June 29, 2017
    Alder BioPharmaceuticals announced that its migraine drug eptinezumab succeeded in a late-stage trial for migraine – but shares immediately fell as investors raised concerns about a strong placebo effect.
PharmaSources Customer Service